Eureka Therapeutics and City of Hope will jointly conduct a Phase 1 clinical trial of assessing Eureka’s investigational CAR T-cell therapy ET1402 for hepatocellular carcinoma (HCC), the most…
SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than Nexavar in a Phase 3 trial.
A new digital support platform, IO Loop, is helping patients stay connected online with doctors before, during, and after treatment. This helps patients track symptoms,…
Coffee consumption can dramatically cut one’ risk of developing hepatocellular carcinoma (HCC), a type of liver cancer, say researchers from Scotland’s University of Edinburgh who…
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for Opdivo…
Those with liver cancer that has spread from the colon have a better chance of surgical removal of their liver tumors after treatment with…
A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver…
Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will…
Researchers at the National University of Singapore have developed a probe that provides doctors with clearer and more accurate magnetic resonance images of liver cancer.
Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial.